An Open-label, Multi-center, Phase 1b/2a Basket Trial of IDX-1197 in Patients with Homologous Recombination Repair Mutated Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Venadaparib (Primary)
Indications Biliary cancer; Breast cancer; Carcinoma; Gastric cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
Focus Therapeutic Use
Acronyms VASTUS
Sponsors Idience; Ildong Pharmaceutical

27 Sep 2024 Status changed from active, no longer recruiting to completed.
06 Jun 2023 Results of an exploratory analysis to explore genetic alterations co-existing with HRR mutation to better predict efficacy from a monotherapy of venadaparib in patients with metastatic pancreatic cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology
28 Feb 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com